- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 504
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease
- Interventions
- Losartan
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 9 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- End Stage Renal Disease
- Interventions
- Erythropoietin, Pentoxifylline
- Drug
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- San Francisco, California • Winston-Salem, North Carolina
- Conditions
- Healthy Volunteers
- Interventions
- AKB-6548, Ferrous Sulfate
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 208
- States / cities
- Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
- Conditions
- Anemia
- Interventions
- Sotatercept, Placebo
- Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 24
- States / cities
- Azusa, California • Glendale, California • La Mesa, California + 16 more
- Conditions
- Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
- Interventions
- Deferasirox
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 1,683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
- Interventions
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate mofetil, Laboratory Biomarker Analysis
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anemia in Chronic Kidney Disease
- Interventions
- JTZ-951
- Drug
- Lead sponsor
- Akros Pharma Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Anaemia
- Interventions
- GSK1278863, rhEPO
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 42
- States / cities
- Paragould, Arizona • Tempe, Arizona • Pine Bluff, Arkansas + 34 more
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbia, South Carolina
- Conditions
- Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Interventions
- Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 507
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Iron therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 36
- States / cities
- Anaheim, California • Cerritos, California • Escondido, California + 31 more
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Anemia, Renal Diseases
- Interventions
- epoetin alfa
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 66
- States / cities
- Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphomas, Low-grade NHL and Chronic Lymphocytic Leukemia
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anemia
- Interventions
- epoetin, methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 14
- States / cities
- Davis, California • Lakewood, Colorado • Atlanta, Georgia + 11 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Renal Anemia
- Interventions
- AND017, Placebo
- Drug
- Lead sponsor
- Kind Pharmaceuticals LLC
- Industry
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
- Conditions
- Anemia
- Interventions
- Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more